Survey of Stereotactic Body Radiation Oncology for Early Staged Non-Small Cell Lung Cancer in China


Purpose: To evaluate the current status of stereotactic body radiotherapy (SBRT) for early staged non-small cell lung cancer (NSCLC) at main cancer hospitals in China. Methods and Materials: The questionnaire was sent by mail and email to 21 hospitals, which include the patient enrollment, treatment technique, dose and fractionation, quality control, disease control and side effects. Results: Nineteen hospitals responded. It was found that SBRT has been used for early staged NSCLC in most of the hospitals participating in the survey. The patient characteristics and techniques were relatively consistent, but there were many controversies regarding dose fractionation and quality control. Conclusions: SBRT for early staged NSCLC has been applied at main cancer hospitals in China. However, considerable variation exists. The establishment of clinical guidelines and standardized quality control are crucial for further improvement.

Share and Cite:

L. Xing, Y. Yin, S. Kong and J. Yu, "Survey of Stereotactic Body Radiation Oncology for Early Staged Non-Small Cell Lung Cancer in China," International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, Vol. 3 No. 1, 2014, pp. 56-59. doi: 10.4236/ijmpcero.2014.31009.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] B. K. Chang and R. D. Timmerman, “Stereotactic Body Radiation Therapy: A Comprehensive Review,” American Journal of Clinical Oncology, Vol. 30, No. 6, 2007, pp. 637-644.
[2] Y. Chen, W. Guo, Y. Lu and B. Zou, “Dose-Individualized Stereotactic Body Radiotherapy for T1-3N0 Non-Small Cell Lung Cancer: Long-Term Results and Efficacy of Adjuvant Chemotherapy,” Radiotherapy & Oncology, Vol. 88, No. 3, 2008, pp. 351-358.
[3] J. P. Grutters, A. G. Kessels, M. Pijls-Johannesma, D. De Ruysscher, M. A. Joore and P. Lambin, “Comparison of the Effectiveness of Radiotherapy with Photons, Protons and Carbon-Ions for Non-Small Cell Lung Cancer: A Meta-Analysis,” Radiotherapy & Oncology, Vol. 95, No. 1, 2010, pp. 32-40.
[4] R. Timmerman, R. Paulus, J. Galvin, J. Michalski, W. Straub, J. Bradley, et al., “Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer,” JAMA, Vol. 303, No. 11, 2010, pp. 1070-1076.
[5] J. He and W. Chen, “2012 Chinese Cancer Registry Annual Report,” Military Medical Science Press, Beijing, 2012.
[6] H. Pan, D. R. Simpson, L. K. Mell, A. J. Mundt and J. D. Lawson, “A Survey of Stereotactic Body Radiotherapy Use in the United States,” Cancer, Vol. 117, No. 19, 2011, pp. 4566-4572.
[7] Y. Nagata, M. Hiraoka, T. Mizowaki, Y. Narita, Y. Matsuo, Y. Norihisa, et al., “Survey of Stereotactic Body Radiation Therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group,” International Journal of Radiation Oncology * Biology * Physics, Vol. 75, No. 2, 2009, pp. 343-347.
[8] M. E. Daly, J. R. Perks and A. M. Chen, “Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States,” Journal of Thoracic Oncology, Vol. 8, No. 2, 2013, pp. 202-207.
[9] J. Zhang, F. J. Yang, B. S. Li, H. S. Li, J. Liu, W. Huang, et al., “Which Is the Optimal Biologically Effective Dose of Stereotactic Body Radiotherapy for Stage I Non-Small-Cell Lung Cancer? A Meta-Analysis,” International Journal of Radiation Oncology * Biology * Physics, Vol. 81, No. 4, 2011, pp. e305-e316.
[10] S. H. Benedict, K. M. Yenice, D. Followill, J. M. Galvin, W. Hinson, B. Kavanagh, et al., “Stereotactic Body Radiation Therapy: The Report of AAPM Task Group 101,” Medical Physic, Vol. 37, No. 8, 2010, pp. 4078-4101.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.